Abeona Q3 net loss $30.3M; FDA sets pz-cel PDUFA Apr 29, 2025

ABEONA THERAPEUTICS INC.

2024-Q3 EPS reported -$1.41

Net loss Q3 2024: $30.3M vs $11.8M YoY; includes $15.2M warrant revaluation loss.
Cash, equivalents and investments $110.0M; down $13M from Q2; cash runway into 2026.
FDA accepted pz-cel BLA resubmission; PDUFA target action date April 29, 2025.
CMS granted pz-cel product-specific code and Pre-MDC MS-DRG 018 reimbursement.
New U.S. patent issued for pz-cel (exp. 2037); lease for added manufacturing capacity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.